Home › NCT04863222

Clinical and Radiographic Success of MTA vs Biodentine

Clinical and Radiographic Success of Mineral Trioxide Aggregate (MTA) vs Septodont Biodentine in Primary Molars in Pulpotomy and Indirect Pulp Cap Treatments

Who can join

Ages 2 to 12 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Male or female patients ages of 2 to ≤12 years.
* Bilateral symptomatic or asymptomatic vital primary molars with caries approximating or into the pulp.
* Patient who need a pulpotomy and/or indirect pulp cap treatments in two or more quadrants.
* Parents of patients who can provide consent in English.
* Patients who need treatment in an operating room setting at Geisinger.

Exclusion Criteria:

* Pre-operative radiographic or clinical symptoms associated with irreversible pulpitis or necrotic pulp.
* Radiographs not displaying furcation region of the tooth.
* Patients with cardiac conditions who need prophylaxis for infective Endocarditis.
* Patients with any type of cancer in the past or present.
* Non-restorable molars.

About the study

The purpose of this prospective study is to compare the clinical and radiographic success of MTA and Biodentine as a medicament in vital pulp therapy in maxillary and mandibular primary molars in a pediatric population. There is limited research currently on Biodentine since it's a novel product. Biodentine is less expensive than MTA and does not cause discoloration like MTA. Biodentine may be an alternative medicament used for vital pulp therapy in primary molars.

What is being tested

• Biodentine (device)
• mineral trioxide aggregate (MTA) (biological)

Sponsor: Geisinger Clinic · Participants: 646 · Started: Nov 12, 2021

Contact the study team

• Gayatri Malik, DMD · Phone: 570-271-6355
• Samantha R Crissinger · Phone: 570-271-7499

Official record on ClinicalTrials.gov — NCT04863222

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.